"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Microsoft Retail Management System (RMS) point of sale AndersenIQ Integration provides a simple solution for retailers selling Andersen windows and doors products. From within Microsoft RMS point of ...

eBook The State of AI in Customer Experience 2025 How AI, human talent and unified platforms are driving up to 20% higher customer satisfaction and measurable ROI. Read now Guide Getting Started with ...

Microsoft announced late last week that it is now offering its Rights Management Service (RMS) commercially, including for premises-based installations. RMS reached the "general availability" release ...

Zenas BioPharma (NASDAQ:ZBIO) shares surged 80% on Monday following the release of highly encouraging Phase 2 results from ...

During the Phase II MoonStone study (NCT06564311), the bifunctional monoclonal antibody (mAb) met its primary endpoint, ...

SAN FRANCISCO--(BUSINESS WIRE)--Nitro, a leading provider of document productivity and collaboration solutions, today announced a new integration with Microsoft RMS (Rights Management Service) to ...

Microsoft group program manager Dan Plastina said "We're thrilled that Nitro released its newest integration with Microsoft RMS in their flagship desktop PDF product, Nitro Pro. "Nitro Pro with RMS ...

– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...

Multiple Sclerosis (MS) is an autoimmune, inflammatory condition of the central nervous system. Relapsing MS (formerly known as Relapsing Remitting MS) is the most common form and constitutes ...

Phase IIIb clinical trial programme of higher-dose OCREVUS (ocrelizumab) to evaluate impact on reducing disability progression in RMS and PPMS Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: ...

75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label ...